Rainbizumab in macular degeneration
Ranibizumab is a medication used for the treatment of age-related macular degeneration (AMD). AMD is a progressive eye condition that affects the macula, which is responsible for central vision.
Ranibizumab is a type of medication called an anti-vascular endothelial growth factor (anti-VEGF) drug. It works by inhibiting the development of abnormal blood vessels in the macula, which is a characteristic of a form of AMD called neovascular or wet AMD.
Wet AMD occurs when abnormal blood vessels grow underneath the macula, leaking blood and fluid, causing damage to the cells responsible for clear central vision. Ranibizumab is injected into the eye to target and neutralize the effects of VEGF, preventing the growth of abnormal blood vessels and reducing further damage to the macula.
Ranibizumab treatment is typically administered by a healthcare professional as a series of injections. The frequency and duration of treatment may vary depending on the individual's specific condition and response to the medication. Regular eye exams and monitoring are necessary to assess the effectiveness of the treatment and determine if any adjustments are needed.
It is important to note that ranibizumab is not a cure for AMD but can help slow down or stabilize the progression of wet AMD, preserving a person's remaining vision. The use of ranibizumab in macular degeneration should always be determined and prescribed by a qualified healthcare professional.